Latest Breaking News On - ஆட்டுக்குட்டி நிறுவனம் - Page 1 : comparemela.com

May 19, 2021 A new bioresorbable scaffold (Firesorb, MicroPort Medical), one with much thinner struts compared with first-generation “dissolving” devices, has shown some early promise in a study of patients with relatively simple coronary artery lesions. Presenting the results of FUTURE II as a late-breaking clinical trial at EuroPCR, Bo Xu, MBBS (National Clinical Research Center for Cardiovascular Disease/Peking Union Medical College, Beijing, China), reported that in this trial, which included operators adhering to a dedicated implantation technique, the bioresorbable scaffold was noninferior to a cobalt-chromium everolimus-eluting stent (Xience; Abbott Vascular) for the primary endpoint of in-segment late lumen loss.   While FUTURE II is a small study looking solely at angiographic outcomes, Xu said he remains optimistic about the technology. “I think, although this is a very small sized study with angiographic outcomes is comparing a new device with a drug-eluting ste

New yorkUnited statesBo xuWilliam wijnsNational clinical research centerPhd lambe institute for translational medicineNational university of ireland galwayCardiovascular disease peking union medical collegeMicroport medicalPeking union medical collegeAbbott vascularIcahn schoolMount sinaiOld is newMean in segment lateLambe institute